AR
Arvinas, Inc.
ARVN · NASDAQ
$9.39 +0.86% (+$0.08)
1M +4.45%
Market Cap $605.9M
P/E Ratio 65.15x
Div. Yield -
ROE 1.91%
Piotroski F-Score Moderate
6/9Valuation
27 /100
Expensive P/S 1.91x
P/E 65.15x
P/B 1.08x
Growth
78 /100
Growing Book val. growth 8.43%
Rev. growth 25.96%
FCF growth N/A
Profitability
25 /100
Weak Op. margin 4.45%
Gross margin 96.43%
FCF margin 65.93%
Quality
10 /100
Poor ROA 1.38%
ROIC 2.18%
Asset turnover 0.47x
Debt
100 /100
Low Net debt/EBITDA -29.76x
Debt/Equity 0.01x
Current ratio 7.91x
Stability
17 /100
Unstable EPS volatility 46.61%
Beta 1.74x
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na ARVN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Randy Teel
Employees
246
Headquarters
New Haven
Nadcházející události
04 LIS
Earnings
Upcoming earnings report